Danaher stock gains support from raised 2026 earnings outlook

Published on 10/30/2026 at 15:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Danaher stock follows stronger third-quarter execution and a raised 2026 adjusted EPS outlook. Respiratory testing remains a drag on reported growth.

Danaher's outlook gains support

Third-quarter revenue rose 8.5 percent year over year to 6.6 billion US dollars.
Adjusted diluted EPS increased 11.5 percent to 2.11 US dollars.
Respiratory testing remains a headwind for reported core growth in the fourth quarter.

Danaher Corp., US2358511028, Illustration mit AI erstellt.

Danaher raised its full-year 2026 adjusted earnings outlook after reporting stronger third-quarter results on October 21. The company said improving end-market trends and operational execution supported the performance.

According to the Danaher investor release, revenue increased 8.5 percent year over year to 6.6 billion US dollars in the quarter ended September 25. Adjusted diluted earnings per share rose 11.5 percent to 2.11 US dollars, while operating cash flow reached 1.9 billion US dollars.

Higher earnings outlook

Danaher lifted its full-year adjusted diluted EPS guidance to 8.57 to 8.62 US dollars from a previous range of 8.45 to 8.60 US dollars. For the fourth quarter, management expects core revenue excluding respiratory revenue to increase 4.0 to 5.0 percent year over year.

Respiratory revenue is expected to reduce fourth-quarter core growth by about 150 basis points, leaving total core growth near 3.0 percent. Danaher also expects an adjusted operating margin of about 29.5 percent in the period.

Danaher stock traded at 209.20 euros on Lang & Schwarz at 15:37:55 CET on Friday, October 30, 2026.

See the real-time quote of Danaher stock for the latest market indication.